Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

Published Date: 02 Feb 2024

Compared to abiraterone, enzalutamide causes more weariness, depression, and slower reaction times.

Read Full News

Latest News

Low Income, Education Tied to Depression in Older Adults

Older adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.

Why Encouragement May Not Improve Motivation in Depression

A meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.

Brexpiprazole Safe, Effective in Early-Episode Schizophrenia

Brexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients with early-episode schizophrenia, new research shows.

Do Anatomy Atlases Reflect Social Inequalities?

Historical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Long-acting injectable antipsychotics are linked to lower rehospitalization rates than oral antipsychotics in patients with bipolar I disorder, a study shows.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

Older adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.

A meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.

Brexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients with early-episode schizophrenia, new research shows.

Historical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Long-acting injectable antipsychotics are linked to lower rehospitalization rates than oral antipsychotics in patients with bipolar I disorder, a study shows.

News All Time

Nasal therapeutic HPV vaccine could prevent cervical cancer

Cervical cancer, which affects the reproductive tract, is one of the most common cancers in women worldwide. It is primarily caused by human papillomavirus (HPV), a viral infection that spreads through sexual contact.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give ...

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled out diabetes before finally ...

Doctors say lung cancer is still the deadliest cancer, but hope is growing

Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in screening, surgery and personalized treatment are helping more patients live longer.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate ...

Best foot forward—chemo care should include podiatry, say researchers

Irreversible nerve damage to the lower limbs is a common side effect of chemotherapy, yet up to 50% of patients are missing out on vital foot care that could significantly ease their symptoms, according to new research from ...

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe that resists the breakdown of certain compounds in the body, giving doctors a more dependable way ...

Depression risk higher among long-term breast cancer survivors than women without breast cancer history

Long-term breast cancer survivors have a higher risk for developing depression, particularly if they have insomnia, according to a study published online Oct. 10 in SLEEPJ.

New study elucidates obesity's role in fueling breast cancer progression

Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood. New research now highlights a molecular chain of events in estrogen receptor-positive breast cancer, ...

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Bacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

Aerobic and resistance exercise can significantly improve physical performance in patients living with metastatic breast cancer, according to new results presented at the Advanced Breast Cancer Eighth International Consensus ...

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...

Radiotherapy after mastectomy can be avoided, study finds

Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.

How access to specialized cancer centers affects glioblastoma outcomes

Glioblastoma is one of the most aggressive and complex brain cancers. It grows quickly, resists standard treatments, and often leaves patients and their families searching for every possible option.

Recommended News For You

The lack of psychiatrists may be addressed by community workers.

Survival is extended by a new treatment option for metastatic colorectal cancer.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines

High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

Recommended Articles For You

Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment 

The benefits and risks of taking fludrocortisone for adrenal insufficiency  

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

2.

Chemo causes lasting physical decline in breast cancer survivors

3.

We Can Advance Our Patients' Healing by One Step With 1,000 Paper Cranes.

4.

Breast awareness: What to look for in your self-exam

5.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

1.

Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact

2.

The Ins and Outs of Glossectomy: What You Need to Know 

3.

Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence

4.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

5.

Introduction to Immune Thrombocytopenic Purpura

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

2.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

4.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot